Drug General Information (ID: DDI1KN7GAB)
Drug Name			Urokinase		Drug Info		Drotrecogin alfa		Drug Info
Drug Type		Protein/peptide				Protein/peptide
Therapeutic Class		Thrombolytics				Coagulation Modifiers

Mechanism of Urokinase-Drotrecogin alfa Interaction (Severity Level: Major)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Urokinase				Drotrecogin alfa
Mechanism		Risk of bleeding Thrombolytic agent				Risk of bleeding Anticoagulant effects
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Urokinase and Drotrecogin alfa

Recommended Action
Management		When making the decision to administer drotrecogin alfa, the increased risk of bleeding versus the benefits of therapy should be carefully considered in seriously ill sepsis patients who have recently (within 3 days) received thrombolytic agents. Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.

References
1	Product Information. Xigris (drotrecogin alfa). Lilly, Eli and Company, Indianapolis, IN.